UNSPSC 51283604: Rifaximin

This classification denotes an antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L36O5T016N. European Medicines Agency schedules Rifaximin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10312MIG. Rifaximin generally arises in the molecular formula C43H51N3O11.

The term RIFAXIMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, no. 6, 1983, list 23.) RIFAXIMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule rifaximin under HS 29419000 and SITC 54139. As of Q4 2014, RIFAXIMIN remains the US FDA Preferred Term for this commodity. Rifaximin bears US NLM identifiers UMLS ID C0073374 and NCI Concept Code C61926.

UNSPSC 51283604 Rifaximin is a Commodity code that nominally addresses a specific pharmaceutical product, but recent state and local opportunities show the code being applied to a much broader pharmaceutical and medical supply procurement landscape. State and local governments buying under this code are actually procuring generic pharmaceuticals, over-the-counter products, emergency medical supplies, naloxone, and related medical consumables through cooperative purchasing alliances, individual county health departments, and municipal fire and rescue divisions. The issuing bodies span state health and human services commissions, county public health agencies, cities, and multistate cooperative purchasing organizations. Work solicited includes competitive bidding for annual pharmaceutical supply agreements with specific National Drug Code requirements, direct-to-manufacturer prescription program development, and fixed-price medical supply contracts for emergency response use. Contracts typically run one to two years with renewal options, require compliance with FDA cGMP standards and Drug Supply Chain Security Act regulations, mandate electronic data interchange capability and specific pricing formats, and impose insurance and performance-penalty requirements on vendors.

Recent activity appears concentrated in Texas, Minnesota, and Florida. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota and Oregon, with pricing evaluations weighted 75 percent on price competitiveness and 25 percent on compliance, EDI capability, and administrative fee structure. Seminole County, Florida released an IFB in June 2026 (due July 26, 2023) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a two-year initial term plus one-year renewal option. The City of Tampa issued a sealed-bid invitation in March 2026 for 169 line items of medical and first aid supplies for the Fire Department Rescue Division with an estimated contract value of $700,000 and a 5 percent bid discount reserved for certified Small Local Business Enterprises (SLBEs). The Texas Health and Human Services Commission posted a Request for Information in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels.